- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00138541
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
February 28, 2017 updated by: Novartis
This is a 28-week extension to a study of the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
The purpose of the extension study is to gather long-term safety and efficacy data for vildagliptin in people with type 2 diabetes.
Study Overview
Study Type
Interventional
Enrollment (Actual)
440
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936
- Novartis Pharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Only patients successfully completing study CLAF237A2301 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion Criteria:
- Premature discontinuation from study CLAF237A2301
- Other protocol-defined exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Change from baseline in HbA1c at 52 weeks
|
|
Safety of vildagliptin during 52 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change in HbA1c between 24 weeks and 52 weeks
|
|
Change in fasting plasma glucose between 24 weeks and 52 weeks
|
|
Change from baseline in fasting plasma glucose at 52 weeks
|
|
Change from baseline in HOMA B at 52 weeks
|
|
Change from baseline in HOMA IR at 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Primary Completion (ACTUAL)
April 1, 2006
Study Completion (ACTUAL)
April 1, 2006
Study Registration Dates
First Submitted
August 27, 2005
First Submitted That Met QC Criteria
August 27, 2005
First Posted (ESTIMATE)
August 30, 2005
Study Record Updates
Last Update Posted (ACTUAL)
March 1, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Vildagliptin
Other Study ID Numbers
- CLAF237A2301E1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.